Uploaded December 2025 | Updated November 2026, 3 hours ago
In this "ABCs of MOGAD" episode, "Steroid Dependence," Krissy Dilger of SRNA was joined by Dr. Eoin Flanagan from the Mayo Clinic in Rochester, MN. They began with a summary of how steroids are used to manage MOG antibody disease, particularly during acute attacks [00:01:25]. Dr. Flanagan described the mechanics of steroids in reducing brain inflammation and the importance of early treatment [00:04:14]. They discussed the concept of steroid dependence and the complications that arise when tapering down the steroid dose [00:05:46]. Dr. Flanagan highlighted alternative treatments to manage steroid dependence and emphasized the importance of working closely with healthcare providers to safely reduce steroid use over time [00:09:42].
Eoin Flanagan, MB, BCh is a Professor of Neurology and Consultant in the departments of Neurology and Laboratory Medicine and Pathology at the Mayo Clinic (Rochester, MN). He completed his medical school training at University College Dublin in Ireland in 2005. He did a medical residency in Ireland and then completed neurology residency, fellowships in neuroimmunology and a master's in clinical and translational science at Mayo Clinic (Rochester, MN). He works in the Autoimmune Neurology and Multiple Sclerosis Clinics and the Neuroimmunology Laboratory at the Mayo Clinic.
His clinical expertise and research are focused on inflammatory myelopathies and their imaging patterns, myelin oligodendrocyte glycoprotein (MOG) antibody associated disorder, neuromyelitis optica spectrum disorders, autoimmune encephalitis, paraneoplastic neurologic disorders, and multiple sclerosis. He is principal investigator on an NIH RO1 grant studying MOG antibody associated disorder.
00:00 Introduction
01:25 Understanding Steroids in MOG Antibody Disease
04:14 Steroid Dosage and Administration
05:46 Steroid Dependence in MOGAD Patients
09:42 Managing Steroid Dependence
14:02 Balancing Inflammation Control and Steroid Risks
17:31 Conclusion
In this "ABCs of MOGAD" episode, "Steroid Dependence," Krissy Dilger of SRNA was joined by Dr. Eoin Flanagan from the Mayo Clinic in Rochester, MN. They began with a summary of how steroids are used to manage MOG antibody disease, particularly during acute attacks [00:01:25]. Dr. Flanagan described the mechanics of steroids in reducing brain inflammation and the importance of early treatment [00:04:14]. They discussed the concept of steroid dependence and the complications that arise when tapering down the steroid dose [00:05:46]. Dr. Flanagan highlighted alternative treatments to manage steroid dependence and emphasized the importance of working closely with healthcare providers to safely reduce steroid use over time [00:09:42].
Eoin Flanagan, MB, BCh is a Professor of Neurology and Consultant in the departments of Neurology and Laboratory Medicine and Pathology at the Mayo Clinic (Rochester, MN). He completed his medical school training at University College Dublin in Ireland in 2005. He did a medical residency in Ireland and then completed neurology residency, fellowships in neuroimmunology and a master's in clinical and translational science at Mayo Clinic (Rochester, MN). He works in the Autoimmune Neurology and Multiple Sclerosis Clinics and the Neuroimmunology Laboratory at the Mayo Clinic.
His clinical expertise and research are focused on inflammatory myelopathies and their imaging patterns, myelin oligodendrocyte glycoprotein (MOG) antibody associated disorder, neuromyelitis optica spectrum disorders, autoimmune encephalitis, paraneoplastic neurologic disorders, and multiple sclerosis. He is principal investigator on an NIH RO1 grant studying MOG antibody associated disorder.
00:00 Introduction
01:25 Understanding Steroids in MOG Antibody Disease
04:14 Steroid Dosage and Administration
05:46 Steroid Dependence in MOGAD Patients
09:42 Managing Steroid Dependence
14:02 Balancing Inflammation Control and Steroid Risks
17:31 Conclusion
![2024 RNDS | What’s my Diagnosis? Physician Panel Discussion Based on Community Panel Presentations
At the 2024 RNDS, a panel of physicians discussed the community panel presentations on their diagnostic journey. The panel collectively discussed the importance of integrating patient stories with clinical perspectives to improve diagnosis and treatment of rare neurologic disorders [00:03:15]. Dr. Carlos Pardo shared historical insights and reviewed the evolution and challenges in understanding and diagnosing transverse myelitis over the past 20 years [00:06:23]. Dr. Dean Wingerchuk highlighted the journey and breakthroughs regarding neuromyelitis optica, emphasizing the significance of biomarkers and new diagnostic criteria [00:18:47]. Dr. Leslie Benson and others delved into acute flaccid myelitis, discussing how it overlaps and differentiates from other conditions, underscoring the importance of precise diagnostic methods and long-term management [00:35:12]. Please note that the information shared during this session is for informational purposes only and is not medical advice.
00:00 Welcome and Introduction
01:13 Historical Perspective on Neurological Disorders
10:52 The Evolution of Neuromyelitis Optica
19:03 The Role of Diagnostic Testing
26:07 Acute Flaccid Myelitis: A New Challenge
37:43 The Importance of Accurate Diagnosis and Long-term Management
42:33 Advice for Patients and Families
46:01 Closing Remarks and Acknowledgements 2024 RNDS | What’s my Diagnosis? Physician Panel Discussion Based on Community Panel Presentations](https://i.ytimg.com/vi/iGsNACIp5Ds/mqdefault.jpg)
![2024 RNDS | Adaptive Tools and Resources
At the 2024 RNDS, Sandy Hanebrink discussed various adaptive tools and resources available for individuals with disabilities, including driving aids, home modifications, and vision technology [00:01:52]. She highlighted innovative devices such as OrCam and Glidance to assist with vision and mobility, as well as affordable solutions for adaptive grips and accessible computer access [00:07:16]. Sandy also mentioned adaptive recreation tools, including wheelchairs and accessible gaming controllers, as well as funding sources for these technologies [00:13:48]. She concluded by informing the audience about the Abilities Expo and providing her contact information for further assistance [00:20:15]. Please note that the information shared during this session is for informational purposes only and is not medical advice.
You can view the presentation slides here:
https://files.wearesrna.org/symposia/2024_rnds/slides/2024RNDS_Hanebrink.pdf
00:00 Introduction and Background
00:32 Adaptive Driving Tools and Resources
01:42 Home Modifications for Accessibility
04:59 Vision Tools and Technologies
10:27 Adaptive Grips and Computer Access
16:22 Accessible Gaming and Mounts
18:04 Wheelchairs and Mobility Aids
20:24 Adaptive Recreation and Sports
23:00 NextGen TV and Accessible Media
25:27 Funding and Resources
27:31 Conclusion and Contact Information 2024 RNDS | Adaptive Tools and Resources](https://i.ytimg.com/vi/ji5uHddIJF8/mqdefault.jpg)





![2024 RNDS | Fatigue and Rare Neuroimmune Disorders
At the 2024 RNDS, Dr. Bardia Nourbakhsh, an MS neurologist, discussed the complexities of fatigue in neuroimmune disorders and highlighted its subjective nature and overlapping symptoms with other conditions like depression and sleepiness [00:03:11]. He emphasized that defining and measuring fatigue is challenging, and current treatment approaches are often inadequate, especially in rare neuroimmune disorders [00:09:01]. Julia Lefelar shared her personal experience with MOG antibody disease (MOGAD) and highlighted the significant impact of fatigue on patients lives [00:20:48]. They answered questions from the audience and underscored the need for more research, patient-reported outcomes, and nonpharmacological treatments like cognitive behavioral therapy and exercise [00:27:08]. Please note that the information shared during this session is for informational purposes only and is not medical advice.
You can view the presentation slides here:
https://files.wearesrna.org/symposia/2024_rnds/slides/2024RNDS_Nourbakhsh.pdf
00:00 Introduction and Opening Remarks
00:31 Julia Lefelars Personal Experience with Fatigue
03:11 Understanding Fatigue in Medical Terms
09:01 Causes and Measurement of Fatigue
12:22 Treatment Approaches for Fatigue
20:48 Fatigue in Rare Neuroimmune Disorders
27:08 Audience Questions and Closing Remarks 2024 RNDS | Fatigue and Rare Neuroimmune Disorders](https://i.ytimg.com/vi/mCabRDJCReU/mqdefault.jpg)


![2026 RNDS | New Diagnostic Criteria Update: Transverse Myelitis
In this session from the 2026 Rare Neuroimmune Disorders Symposium (RNDS), Kyle Blackburn, MD, of the University of Texas Southwestern, spoke about the proposed update to the 2002 diagnostic criteria for transverse myelitis (TM) [00:02:00]. Dr. Blackburn explained why the criteria need revising, including acute flaccid myelitis (AFM) and the discovery of aquaporin-4 and MOG antibodies [00:04:06]. He described the proposal to say myelitis and name the cause, such as MOG antibody disease (MOGAD), with idiopathic used when no cause is found [00:12:48]. He walked through the proposed steps: confirming a spinal cord problem, MRI and spinal fluid testing, the timing of symptoms, and a list of conditions that can look like myelitis [00:16:04]. He shared the journal comments the group received, then answered questions about people diagnosed with TM years ago, repeat testing, 7T MRI, and finding care [00:28:14].
Kyle Blackburn, MD, is an assistant professor in the Department of Neurology at UT Southwestern Medical Center in Dallas, Texas. He earned his medical degree at the University of Kentucky College of Medicine, completed his neurology residency at UT Southwestern, and stayed to complete a fellowship in neuroimmunology, where he trained with Dr. Greenberg and earned the James T. Lubin Clinician Scientist Award from the Siegel Rare Neuroimmune Association (SRNA). During his fellowship he launched the Comprehensive Outcome Registry Exploring Transverse Myelitis (CORE TM) study, and he joined the UT Southwestern faculty in 2020.
Benjamin Greenberg, MD, MHS, is Vice Chair of Translational Research and Strategic Initiatives and Director of the Transverse Myelitis and Neuromyelitis Optica Program at UT Southwestern Medical Center and Childrens Medical Center Dallas. He is recognized internationally as an expert in rare autoimmune disorders of the central nervous system, including transverse myelitis, neuromyelitis optica spectrum disorder, and acute disseminated encephalomyelitis, and he sees both adults and children in his clinical practice.
00:00 Welcome and Speaker Introduction
02:00 Why Update the 2002 Criteria
07:50 What Has Changed Since 2002
11:04 What New Criteria Need to Include
12:48 From Transverse Myelitis to Myelitis
16:04 Confirming a Spinal Cord Problem
20:44 Evidence of Inflammation
23:20 Diagnosing Myelitis in 2026
28:14 Where the Criteria Stand Now
30:34 Questions from the Audience
42:42 Closing Thoughts 2026 RNDS | New Diagnostic Criteria Update: Transverse Myelitis](https://i.ytimg.com/vi/nI5hUAB_uug/mqdefault.jpg)